CIMREAL
Research type
Research Study
Full title
A Multicenter, non-interventional, prospective study to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis in daily practice (CIMREAL)
IRAS ID
269550
Contact name
Philip Laws
Contact email
Sponsor organisation
UCB Bioscience GmbH
Clinicaltrials.gov Identifier
243324, Parexel ref
Duration of Study in the UK
2 years, 5 months, 31 days
Research summary
Psoriasis (PSO) is a common, chronic inflammatory skin disease. In addition to the impact on skin, PSO has a multitude of psychosocial and emotional effects on patients, including increased self-consciousness, frustration, fatigue, depression, and suicidal ideation. As a result, patients frequently report sleeping problems, difficulties at work, problems interacting with family members, disrupted leisure activities, and sexual difficulties.
Plaque PSO is the most common type of psoriasis, comprising approximately 80% to 90% of all cases.
This study will look at effectiveness of Certolizumab pegol (CZP) in patients with moderate to severe plaque PSO as part of routine clinical practice.
The study will also assess the impact of CZP on quality of life.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
19/NW/0555
Date of REC Opinion
20 Sep 2019
REC opinion
Further Information Favourable Opinion